Cargando…
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials
The Lugano 2014 criteria are the standard for response assessment in lymphoma. We compared the prognostic performance of Lugano 2014 and the more recently developed response evaluation criteria in lymphoma (RECIL 2017), which relies primarily on computed tomography and uses unidimensional measuremen...
Autores principales: | Kostakoglu, Lale, Martelli, Maurizio, Sehn, Laurie H., Davies, Andrew, Trněný, Marek, Herold, Michael, Vitolo, Umberto, Hiddemann, Wolfgang, Trotman, Judith, Knapp, Andrea, Mattiello, Federico, Nielsen, Tina G., Sahin, Deniz, Sellam, Gila, Ward, Carol, Younes, Anas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660391/ https://www.ncbi.nlm.nih.gov/pubmed/38024624 http://dx.doi.org/10.1002/jha2.796 |
Ejemplares similares
-
A prognostic model integrating PET‐derived metrics and image texture analyses with clinical risk factors from GOYA
por: Kostakoglu, Lale, et al.
Publicado: (2022) -
A phase 1 first‐in‐human study of GS‐0189, an anti‐signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non‐Hodgkin lymphoma (NHL)
por: Narkhede, Mayur, et al.
Publicado: (2023) -
Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020) -
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study
por: Kostakoglu, Lale, et al.
Publicado: (2021) -
Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma
por: Torka, Pallawi, et al.
Publicado: (2020)